Physician profile
Ronald C Gobeil
NPI 1003926452
$3,412.30
in general payments reported to CMS, 2019-2025
17 companies · $866 in 2025
The $866 reported for 2025 was more than what 79% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $280 · 2021: $1,011 · 2022: $459 · 2023: $332 · 2024: $340 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,525 · Education: $13.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,524.74 |
| Education | $13.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,187.96 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $389.50 | 2020-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $341.49 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $312.21 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $305.69 | 2019-2023 | Invega Sustenna |
| Lundbeck LLC | $235.59 | 2020-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $145.56 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $98.78 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $83.55 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $74.59 | 2021-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $64.05 | 2025 | Austedo Xr |
| Alkermes, INC. | $48.27 | 2023-2024 | Vivitrol, Vivitrol |
| Merck Sharp & Dohme LLC | $35.92 | 2020-2022 | |
| Pfizer INC. | $27.02 | 2023 | |
| Idorsia Pharmaceuticals US INC | $24.39 | 2023 | Quviviq |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $23.12 | 2025 | Qelbree |
| Avanir Pharmaceuticals, INC. | $14.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Gobeil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.